CAR-T has revolutionized the treatment options for blood cancers but its application for solid tumors has fallen short. The German biotech hopes that by combining a CAR-T cell therapy with an mRNA vaccine could be a gamechanger.
Building on the success of its Pfizer Inc.-partnered COVID-19 vaccine Comirnaty, BioNTech SE has presented a promising update on its first CAR-T candidate, both alone and in combination with an mRNA vaccine, as a potential treatment for certain solid tumors.
The German biotech has presented initial data from its ongoing first-in-human Phase I/II trial at the American Association for Cancer Research (AACR) congress in New Orleans evaluating BNT211 in patients...
The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.
The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.
Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.
